Post by Yelk on Jan 28, 2015 3:34:14 GMT
I have been searching for companies at the very lowest to establish small positions in and add over long periods of time. It is my goal to establish multiples of these over 3-4 year max time frames and have them cycle through as I continue to find new ones. This company is yet another trading at cash value and IMO it is very undervalued. Some cash may be used for the trial which will commence soon but the good entry point as of this week is a) 52 week low and b) trial has been enrolling for a very long time now (avoided a year ago share value drop and no catalysts). Also see reservlogix post for more "long" companies I'm interested in that I believe are undervalued with large upside and limited downside. Cheers 
Much more research to do at this point but just finding the basics of what I like to see before doing phase 2 research.
About:
ARCA biopharma is dedicated to developing genetically-targeted therapies for cardiovascular diseases. The Company's lead product candidate, GencaroTM (bucindolol hydrochloride), is an investigational, pharmacologically unique beta-blocker and mild vasodilator being developed for the prevention of atrial fibrillation (“AF”) in patients with heart failure and reduced left ventricular ejection fraction ("HFREF").
Visit: for more information: www.arcabiopharma.com/index-2.html
The rundown:
~$0.76 PPS
~17.2M cash
~21M shares outstanding
~14M float
~16M Market cap
~Relatively strong volumes and activities
~Seemingly off the radar
- Stock at 52 week low
-74% Success rate on prior trial
~Awaiting trial progress announcements/partnerships
The trial: clinicaltrials.gov/ct2/show/NCT01970501?term=arca&rank=1
Seeking alpha article read: seekingalpha.com/article/2298585-arca-biopharma-an-undervalued-biotech-with-a-bright-future
The article goes over why the shares have fallen, identifies this as "a long" and shows the undervalue + potential value of the stock.
Much more research to do at this point but just finding the basics of what I like to see before doing phase 2 research.About:
ARCA biopharma is dedicated to developing genetically-targeted therapies for cardiovascular diseases. The Company's lead product candidate, GencaroTM (bucindolol hydrochloride), is an investigational, pharmacologically unique beta-blocker and mild vasodilator being developed for the prevention of atrial fibrillation (“AF”) in patients with heart failure and reduced left ventricular ejection fraction ("HFREF").
Visit: for more information: www.arcabiopharma.com/index-2.html
The rundown:
~$0.76 PPS
~17.2M cash
~21M shares outstanding
~14M float
~16M Market cap
~Relatively strong volumes and activities
~Seemingly off the radar
- Stock at 52 week low
-74% Success rate on prior trial
~Awaiting trial progress announcements/partnerships
The trial: clinicaltrials.gov/ct2/show/NCT01970501?term=arca&rank=1
Seeking alpha article read: seekingalpha.com/article/2298585-arca-biopharma-an-undervalued-biotech-with-a-bright-future
The article goes over why the shares have fallen, identifies this as "a long" and shows the undervalue + potential value of the stock.
